Trial Profile

An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MGY 825 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

Most Recent Events

10 Sep 2024 Planned End Date changed from 17 Aug 2026 to 28 Jul 2027.
10 Sep 2024 Planned primary completion date changed from 17 Aug 2026 to 28 Jul 2027.
28 Aug 2023 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com